

2024

# Update on the Multimodality Management of Bladder and Kidney Cancer


NOVEMBER 21—23

In-Person / Virtual  
Zuckerman Research Center  
New York City

Highlights include a keynote on new standards of managing advanced urothelial cancer, updated trial data, and surgical video sessions.



Memorial Sloan Kettering  
Cancer Center



# Overview

**This program is designed to highlight the latest developments in the multidisciplinary management of bladder and kidney cancers. The aim of the course is provide attendees with information that will aid in the delivery of state-of-the-art care to patients with all stages of bladder and kidney cancers.**

Highlights of this year's program include:

- Management strategies for localized kidney cancer and non-muscle invasive bladder cancer
- Neoadjuvant and adjuvant systemic therapies for muscle-invasive bladder cancer
- Treatment paradigms for advanced kidney cancer and optimal surgical approaches for high-risk cases
- Advanced imaging modalities for kidney cancer
- The role of intraoperative and SBRT techniques for treating bladder and kidney cancers
- A review of hereditary kidney cancer syndromes

The keynote presentation will detail the new standards in managing advanced urothelial cancer. Updated trial data will be presented, detailing recent changes in the standard of care for advanced urothelial cancer, focusing on combination therapies that include novel antibody-drug conjugates and checkpoint inhibitors.

Additionally, the program will include video sessions that highlight surgical techniques for urinary diversion, utilizing both open and robotic methods, as well as radical nephrectomy with thrombectomy.

## Format and Target Audience

Attendees can choose to participate either in person at Memorial Sloan Kettering Cancer Center or virtually via Zoom. This course is intended for urologists, urologic-oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, nurses, and other healthcare professionals.

## Educational Objectives

At the conclusion of this program, attendees will be able to:

- Present a multidisciplinary approach to the management of bladder and kidney cancer including surgical, medical, and radiation therapies
- Disseminate knowledge of new approaches to the multidisciplinary management of bladder and kidney cancer
- Integrate new therapeutics into the treatment of localized, locally advanced, and metastatic bladder and kidney cancers

## Accreditation

The following Continuing Medical Education (CME) credits will be available for this program:

**AMA PRA Category 1 Credits™**

**ABIM MOC**


**ABPath CC**

**ABS CC**

An application for **NCPD** credits has been submitted.



## MSK Course Directors



### **Bernard H. Bochner, MD, FACS**

Sir Murray F. Brennan Chair in Surgery  
Attending, Urology Service  
Department of Surgery



### **Jonathan E. Rosenberg, MD**

Chief Attending, Genitourinary Oncology Service  
Enno W. Ercklentz, Jr. Chair  
Department of Medicine

## MSK Course Planners

### **Maria Carlo, MD**

Assistant Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Muhammad Hassan Alkazemi, MD**

Urologic Surgical Oncology Fellow

### **Sahil D. Doshi, MD**

Medical Oncology/Hematology Fellow

### **Daniel Gorovets, MD**

Assistant Attending,  
External Beam Radiotherapy Service  
Department of Radiation Oncology

### **Aditi Gupta, MD**

Hematology Oncology Fellow

### **A. Ari Hakimi, MD**

Associate Attending, Urology Service  
Department of Surgery

### **Gopa Iyer, MD**

Section Head, Bladder Cancer  
Associate Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Marisa A. Kollmeier, MD**

Chief, Brachytherapy Service  
Program Director, Brachytherapy Fellowship  
Attending, External Beam Radiotherapy Service  
Department of Radiation Oncology

### **Vashti Livingston, BS, MS, CWOCN**

Clinical Nurse, Urology Outpatient Center

### **Robert J. Motzer, MD**

Section Head, Kidney Cancer,  
Genitourinary Oncology Service  
Jack & Dorothy Byrne Chair in Clinical Oncology  
Attending, Genitourinary Oncology Service  
Department of Medicine

### **Eugene Pietzak, MD**

Assistant Attending, Urology Service  
Department of Surgery  
Department of Medicine

### **Martin H. Voss, MD**

Associate Attending; Clinical Director,  
Genitourinary Medical Oncology Service  
Department of Medicine

### **Michal Sternschuss, MD**

Genitourinary Oncology Fellow



Memorial Sloan Kettering  
Cancer Center

## Invited Faculty



### **Phillip M. Pierorazio, MD**

Chief, Section of Urology, Penn Presbyterian Medical Center  
Professor of Surgery, University of Pennsylvania

## MSK Faculty

### **David H. Aggen, MD, PhD**

Assistant Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Dean F. Bajorin, MD**

Frederick R. Adler Senior Faculty Chair  
Attending, Genitourinary Oncology Service  
Department of Medicine

### **Eugene K. Cha, MD**

Associate Attending, Urology Service  
Department of Surgery

### **Jonathan A. Coleman, MD**

David H. Koch Chair  
Attending, Urology Service  
Department of Surgery

### **Timothy F. Donahue, MD**

Associate Attending, Urology Service  
Department of Surgery

### **S. Machele Donat, MD, FACS**

Attending, Urology Service  
Department of Surgery

### **Darren R. Feldman, MD**

Section Head, Germ Cell Cancer  
Associate Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Samuel A. Funt, MD**

Assistant Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Alvin C. Goh, MD**

Director, Robotic Urologic Surgery  
Technology and Education  
Associate Attending, Urology Service  
Department of Surgery

### **Daniel Gorovets, MD**

Assistant Attending,  
External Beam Radiotherapy Service  
Department of Radiation Oncology

### **Allison Gordon, MD**

Assistant Attending, Dermatology Service  
Department of Medicine

### **Ritesh R. Kotecha, MD**

Assistant Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Daniel E. Lage, MD, MBA, MSc**

Assistant Attending,  
Genitourinary Oncology Service  
Department of Medicine

### **Alicia Latham, MD, MS**

Medical Director, MSK-CATCH  
Assistant Attending,  
Clinical Genetics Service  
Department of Medicine



Memorial Sloan Kettering  
Cancer Center

**Himanshu Nagar, MD, MS**

Director, Genitourinary Program  
Associate Attending  
Department of Radiation Oncology

**Neeta Pandit-Taskar, MD**

Director, Nuclear Medicine Pediatrics  
Attending, Molecular Imaging and  
Therapy Service  
Department of Radiology

**Fourat Ridouani, MD**

Assistant Attending,  
Interventional Radiology Service  
Department of Radiology

**Paul Russo, MD, FACS**

Attending, Urology Service  
Department of Surgery

**Neil J. Shah, MBBS**

Assistant Attending,  
Solid Tumor Genitourinary Service  
Department of Medicine

**Yoshiya (Josh) Yamada, MD**

Co-Chief, Multi-Disciplinary  
Spine Tumor Service  
Attending, External Beam  
Radiotherapy Service  
Department of Radiation Oncology

**Randy Yeh, MD**

Associate Attending,  
Molecular Imaging and Therapy Service  
Department of Radiology

**Mitigation of Relevant Financial Relationships**

Memorial Sloan Kettering Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.



# DAY 1

## THURSDAY • NOVEMBER 21

12:30 PM REGISTRATION AND CHECK-IN  
Virtual Sign-On begins at 12:45 PM

12:50 PM **Introduction and Welcome Remarks**  
Bernard H. Bochner, MD, FACS  
Jonathan E. Rosenberg, MD

### Localized Kidney Cancer (I)

1:00 PM **Current Surgical Paradigms in the Management of Small Renal Masses**  
Jonathan A. Coleman, MD

1:15 PM **Surveillance Strategies for Small Renal Masses**  
Phillip M. Pierorazio, MD

1:30 PM **SBRT as a Strategy to Treat Renal Masses in the Non-Metastatic Setting**  
Daniel Gorovets, MD

1:45 PM **Ablation Strategies for Small Renal Masses**  
Fourat Ridouani, MD

### Localized Kidney Cancer (II)

2:00 PM **Atypical Recurrences Following Minimal Invasive Kidney Surgeries**  
Paul Russo, MD, FACS

2:15 PM **Localized Kidney Cancer (I & II)**  
**Panel Discussion/Q&A and Case Presentations**  
Jonathan A. Coleman, MD  
Daniel Gorovets, MD  
Phillip M. Pierorazio, MD  
Fourat Ridouani, MD

2:45 PM BREAK

## Non-Muscle Invasive Bladder Cancer (NMIBC)

- 3:00 PM **Current Status of BCG Shortage:  
Management Alternatives and Strategies for NMIBC**  
Alvin C. Goh, MD
- 3:15 PM **Role for White Light Enhanced Technologies for  
Bladder Cancer Detection and Treatment**  
Bernard H. Bochner, MD, FACS
- 3:30 PM **Emerging Role of Urinary Markers for NMIBC Detection**  
Eugene K. Cha, MD
- 3:45 PM **Update on Treatment Options for BCG  
Unresponsive NMIBC**  
Eugene Pietzak, MD
- 4:00 PM **Panel Discussion/Q&A and Case Presentations**  
Bernard H. Bochner, MD, FACS  
Eugene K. Cha, MD  
Alvin C. Goh, MD  
Eugene Pietzak, MD
- 4:45 PM **VIDEO SESSION**  
**Tips and Tricks for Continent Urinary Diversion**  
Bernard H. Bochner, MD, FACS  
Eugene K. Cha, MD  
Timothy F. Donahue, MD  
Alvin C. Goh, MD  
Eugene Pietzak, MD
- 5:15 PM **Closing Remarks and Adjourn**  
Jonathan E. Rosenberg, MD

### NETWORKING RECEPTION

We invite attendees to a networking reception from 5:15—6:15 PM  
in the lobby with hors d'oeuvres and refreshments.

RSVP at registration.




# DAY 2

## FRIDAY • NOVEMBER 22

7:15 AM NETWORKING BREAKFAST  
Virtual Sign-On begins at 7:55 AM

8:00 AM **Welcome Remarks**  
Bernard H. Bochner, MD, FACS

### Keynote Address and Medicine Grand Rounds

8:05 AM  **New Standards in the Management of Advanced Urothelial Cancer**  
Jonathan E. Rosenberg, MD

8:50 AM **Discussion/Q&A**

9:00 AM BREAK

### Localized Bladder Cancer (I)

9:30 AM **Updates in Neoadjuvant Therapy for Muscle Invasive Bladder Cancer**  
David H. Aggen, MD, PhD

9:45 AM **Review of Randomized Trial Data for the Role of Pelvic Lymph Node Dissection in Muscle Invasive Bladder Cancer**  
Bernard H. Bochner, MD, FACS

10:00 AM **Contemporary QOL After Radical Cystectomy and Urinary Diversion: MSK Prospective Trial Data**  
Timothy F. Donahue, MD

10:15 AM **Modern ERAS Protocols for Radical Cystectomy**  
Alvin C. Goh, MD

10:30 AM **The Role of Adjuvant Therapy for High-Risk Muscle Invasive Bladder Cancer**  
Dean F. Bajorin, MD

10:45 AM **Enhancing Outpatient Support to Improve Outcomes in Bladder Cancer**  
Daniel E. Lage, MD, MBA, MSc

## Locally Advanced Kidney Cancer

- 11:00 AM Contemporary Nuclear Medicine Diagnostics in Renal Cell Carcinoma  
Neeta Pandit-Taskar, MD
- 11:10 AM Management of IVC Thrombi in the Era of Immunotherapy  
A. Ari Hakimi, MD
- 11:20 AM Pivotal Data for Adjuvant Immunotherapy in Resected Renal Cell Carcinoma  
Robert J. Motzer, MD

11:30 AM **Panel Discussion/Q&A and Case Presentations**  
A. Ari Hakimi, MD  
Robert J. Motzer, MD  
Neeta Pandit-Taskar, MD

11:50 AM NETWORKING LUNCH

## Metastatic Kidney Cancer (I)

- 1:00 PM Current Paradigms in the Management of Newly Diagnosed Metastatic Renal Cell Carcinoma  
Neil J. Shah, MBBS
- 1:30 PM Contemporary Standards in the Treatment of Refractory Renal Cell Carcinoma  
Martin H. Voss, MD

1:45 PM **Panel Discussion/Q&A and Case Presentations**  
A. Ari Hakimi, MD  
Neil J. Shah, MBBS  
Martin H. Voss, MD

## Localized Bladder Cancer (II)

- 2:15 PM **Bladder Preservation Options for Muscle Invasive Bladder Cancer:**
- I. Systemic Therapy Alone  
Gopa Iyer, MD
  - II. Partial Cystectomy  
S. Machele Donat, MD, FACS
  - III. Trimodality Therapy  
Marisa A. Kollmeier, MD

3:00 PM **New Approaches for High Risk Localized Upper Tract Urothelial Cancer**  
Gopa Iyer, MD

3:15 PM **Impact of Variant Histology on Urothelial Cancer Treatment**  
Samuel A. Funt, MD

3:30 PM **Localized Bladder Cancer (I & II)**  
**Panel Discussion/Q&A and Case Presentations**

David H. Aggen, MD, PhD  
Dean F. Bajorin, MD  
Bernard H. Bochner, MD, FACS  
Timothy F. Donahue, MD  
S. Machele Donat, MD, FACS  
Alvin C. Goh, MD  
Samuel A. Funt, MD  
Gopa Iyer, MD  
Marisa A. Kollmeier, MD  
Daniel E. Lage, MD, MBA, MSc

4:15 PM **Closing Remarks and Adjourn**  
Jonathan E. Rosenberg, MD

# DAY 3

## SATURDAY • NOVEMBER 23

8:00 AM NETWORKING BREAKFAST  
Virtual Sign-On begins at 8:20 AM

8:25 AM **Welcome Remarks**  
Jonathan E. Rosenberg, MD

### Localized and Metastatic Bladder Cancer

8:30 AM **Role for Surgery in Advanced Disease**  
Eugene K. Cha, MD

8:45 AM **Molecular Imaging for Bladder Cancer:  
Now and Future**  
Randy Yeh, MD

9:00 AM **Later Line Therapies**  
Gopa Iyer, MD

9:15 AM **Management of Skin Toxicities of Antibody Drug  
Conjugates and Immune Checkpoint Inhibitors**  
Allison Gordon, MD

9:30 AM **Panel Discussion/Q&A**  
Eugene K. Cha, MD  
Allison Gordon, MD  
Gopa Iyer, MD  
Randy Yeh, MD

9:45 AM Break

### Metastatic Kidney Cancer (II)

10:00 **Management of Brain and Spinal Cord Metastases  
Using Contemporary Radiation Strategies**  
Yoshiya (Josh) Yamada, MD

10:15 AM **Novel Approaches in the Systemic Treatment of Advanced  
Renal Cell Carcinoma**  
Ritesh R. Kotecha, MD

10:30 AM **SBRT to non-CNS sites in the Management of  
Advanced Kidney Cancer**  
Himanshu Nagar, MD, MS

10:45 AM

**Panel Discussion/Q&A and Case Presentations**

Ritesh R. Kotecha, MD  
Himanshu Nagar, MD, MS  
Yoshiya (Josh) Yamada, MD

**Hereditary Genitourinary Syndromes  
and Renal Cell Carcinoma**

11:00 AM

**Hereditary Syndromes with Predisposition to  
Bladder and Kidney Cancers**

Alicia Latham, MD, MS

11:30 AM

**Systemic Treatment for Uncommon Kidney  
Cancer Variants**

Darren R. Feldman, MD

11:45 AM

**Panel Discussion/Q&A**

Darren R. Feldman, MD  
Alicia Latham, MD, MS

12:00 PM

**Closing Remarks and Adjourn**

Bernard H. Bochner, MD, FACS  
Jonathan E. Rosenberg, MD



# Registration

Participants of this course have the option to attend either in person at the Zuckerman Research Center (417 East 68th Street, New York City) or virtually via Zoom.

In-person registrants will be provided continental breakfast, lunch, and refreshment breaks. Contact [cme@mskcc.org](mailto:cme@mskcc.org) at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

**Discounted registration is available for specific groups.**

Visit the course website for additional details.

Registration Fees	Early	General
Physicians (MDs, PhDs, and DOs)	\$550	\$600
Advanced Practice Providers	\$400	\$450
Residents, and Fellows	\$350	\$400
Nurses and Other Healthcare Providers	\$300	\$350
Industry Professionals*	n/a	\$1,050
MSK Employees	Complimentary	

**Early discounted rates available through October 25.**

\*An “industry professional” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.

To register, scan the QR code or visit:

[msk.org/BladderKidneyCancers](https://msk.org/BladderKidneyCancers)



# Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

## AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of **14.00 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **14.00 credits/points** in the following certification programs:

- Medical Knowledge MOC points in the American Board of Internal Medicine's (**ABIM**) Maintenance of Certification Assessment Recognition Program; and
- Lifelong Learning (Part II) credits for the American Board of Pathology (**ABPath**) Continuing Certification program; and
- Accredited CME and Self-Assessment credits for the American Board of Surgery (**ABS**) Continuous Certification program.

MOC/CC points will be reported to your board within 45 days upon completion of the course.

**An application for NCPD credits has been submitted.**





Memorial Sloan Kettering  
Cancer Center